NO994463L - Antitumoraktivitetsforsterkningsmetode av uforedlede naturlegemidler, sammensetning som inneholder uforedlede naturlegemiddelforsterkningsantitumoraktivitet, evaluering av metode for antitumoreffektivitet ved behandling med uforedlet naturlegemi - Google Patents

Antitumoraktivitetsforsterkningsmetode av uforedlede naturlegemidler, sammensetning som inneholder uforedlede naturlegemiddelforsterkningsantitumoraktivitet, evaluering av metode for antitumoreffektivitet ved behandling med uforedlet naturlegemi

Info

Publication number
NO994463L
NO994463L NO994463A NO994463A NO994463L NO 994463 L NO994463 L NO 994463L NO 994463 A NO994463 A NO 994463A NO 994463 A NO994463 A NO 994463A NO 994463 L NO994463 L NO 994463L
Authority
NO
Norway
Prior art keywords
unprocessed
enhancement
antitumor
antitumor activity
herbal
Prior art date
Application number
NO994463A
Other languages
English (en)
Norwegian (no)
Other versions
NO994463D0 (no
Inventor
Niwa Kozo
Original Assignee
Niwa Kozo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niwa Kozo filed Critical Niwa Kozo
Publication of NO994463D0 publication Critical patent/NO994463D0/no
Publication of NO994463L publication Critical patent/NO994463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO994463A 1998-09-17 1999-09-15 Antitumoraktivitetsforsterkningsmetode av uforedlede naturlegemidler, sammensetning som inneholder uforedlede naturlegemiddelforsterkningsantitumoraktivitet, evaluering av metode for antitumoreffektivitet ved behandling med uforedlet naturlegemi NO994463L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (ja) 1998-09-17 1998-11-13 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法

Publications (2)

Publication Number Publication Date
NO994463D0 NO994463D0 (no) 1999-09-15
NO994463L true NO994463L (no) 2000-03-20

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994463A NO994463L (no) 1998-09-17 1999-09-15 Antitumoraktivitetsforsterkningsmetode av uforedlede naturlegemidler, sammensetning som inneholder uforedlede naturlegemiddelforsterkningsantitumoraktivitet, evaluering av metode for antitumoreffektivitet ved behandling med uforedlet naturlegemi

Country Status (19)

Country Link
JP (1) JP2000159682A (nl)
KR (1) KR20000023206A (nl)
CN (1) CN1255376A (nl)
AU (1) AU4486299A (nl)
BE (1) BE1012725A5 (nl)
CA (1) CA2282234A1 (nl)
DE (1) DE19944695A1 (nl)
DK (1) DK199901235A (nl)
ES (1) ES2155802B1 (nl)
FR (2) FR2783426A1 (nl)
GB (2) GB9920710D0 (nl)
ID (1) ID23150A (nl)
IL (1) IL131722A0 (nl)
IS (1) IS5183A (nl)
IT (1) IT1307267B1 (nl)
NL (2) NL1013049C2 (nl)
NO (1) NO994463L (nl)
SE (2) SE9903307L (nl)
SG (1) SG76631A1 (nl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087603A1 (fr) * 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Immunostimulants
CA2445713A1 (en) * 2001-05-07 2002-11-14 Gab-Gyun Shin A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
JP4499979B2 (ja) * 2001-05-21 2010-07-14 コンビ株式会社 病原菌感染抑制用組成物
JP4561098B2 (ja) * 2001-06-01 2010-10-13 味の素株式会社 糖尿病用薬剤
JP4826696B2 (ja) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 血管新生阻害剤
JP4681801B2 (ja) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 血管新生阻害剤およびその製造方法
KR100971599B1 (ko) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 혈관 관련 질환의 예방 또는 치료를 위한 조성물
JP2005089417A (ja) * 2003-09-19 2005-04-07 Noevir Co Ltd 糖尿病予防・治療用組成物
JP4587441B2 (ja) * 2004-02-12 2010-11-24 株式会社クレハ 新規な糖尿病治療剤および食品
JP5034071B2 (ja) * 2004-09-17 2012-09-26 株式会社Ｓ・Ｓ・Ｉ 乳癌を抑制するカワリハラタケ抽出物
JP2006273835A (ja) * 2005-03-04 2006-10-12 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
WO2011014729A1 (en) * 2009-07-31 2011-02-03 Yukiguni Maitake Co., Ltd. Maitake mushroom coffee
JPWO2011081024A1 (ja) * 2009-12-29 2013-05-09 株式会社富士見養蜂園 旨味食品及びその製造方法
CN106333969A (zh) * 2016-08-30 2017-01-18 青海民族大学 圆孢蘑菇抑制hdac1酶有效部位及制法和应用
CN106309511A (zh) * 2016-08-30 2017-01-11 青海民族大学 圆孢蘑菇抑制cdc25酶有效部位及制法和应用
US20200397817A1 (en) * 2017-11-30 2020-12-24 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102602787B1 (ko) * 2020-12-16 2023-11-17 대한민국 꽃송이버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102646421B1 (ko) * 2020-12-16 2024-03-12 대한민국 잎새버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102584680B1 (ko) * 2020-12-17 2023-10-06 대한민국 생리활성 및 영양성분이 증가된 표고버섯차 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (de) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Energetische anregung biologischer arzneimittel
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (ja) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍機能を有する食品及びその製造法
JP3357383B2 (ja) * 1991-08-14 2002-12-16 昌宏 黒田 低分子化植物性組成物
JP2955126B2 (ja) * 1992-06-22 1999-10-04 笑代 丹羽 医薬用油性製剤、食品用油性製剤およびそれらの製造方法
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
GB9920710D0 (en) 1999-11-03
DE19944695A1 (de) 2000-03-30
KR20000023206A (ko) 2000-04-25
ES2155802A1 (es) 2001-05-16
NL1019705C2 (nl) 2002-03-26
NO994463D0 (no) 1999-09-15
CA2282234A1 (en) 2000-03-17
GB9921387D0 (en) 1999-11-10
SG76631A1 (en) 2000-11-21
DK199901235A (da) 2000-03-18
JP2000159682A (ja) 2000-06-13
NL1019705A1 (nl) 2002-01-29
FR2788697A1 (fr) 2000-07-28
GB2341800A (en) 2000-03-29
FR2783426A1 (fr) 2000-03-24
SE9903307L (sv) 2000-03-18
IL131722A0 (en) 2001-03-19
ITTO990784A0 (it) 1999-09-14
CN1255376A (zh) 2000-06-07
SE9903307D0 (sv) 1999-09-16
IT1307267B1 (it) 2001-10-30
ID23150A (id) 2000-03-23
ITTO990784A1 (it) 2001-03-14
ES2155802B1 (es) 2001-12-01
NL1013049A1 (nl) 2000-03-21
SE0100195D0 (sv) 2001-01-24
AU4486299A (en) 2000-03-30
BE1012725A5 (fr) 2001-02-06
SE0100195L (sv) 2001-01-24
NL1013049C2 (nl) 2002-01-11
IS5183A (is) 2000-03-17

Similar Documents

Publication Publication Date Title
NO994463L (no) Antitumoraktivitetsforsterkningsmetode av uforedlede naturlegemidler, sammensetning som inneholder uforedlede naturlegemiddelforsterkningsantitumoraktivitet, evaluering av metode for antitumoreffektivitet ved behandling med uforedlet naturlegemi
Blom et al. Acupuncture treatment of patients with radiation-induced xerostomia
Carbone et al. Constitutional nonhemolytic hyperbilirubinemia in the rat: defect of bilirubin conjugation
Vetulani et al. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain
Malhotra et al. Nicotine and periodontal tissues
ATE319457T1 (de) Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
NO973059L (no) Hydroksylaminderivater som er anvendbare for å öke den molekylære chaperonproduksjon, og fremstilling derav
NO20003051L (no) Metode for administrering av AspB28-humant insulin
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
SE9404196D0 (sv) New antithrombotic formulation
Bernhard et al. Psychosocial issues in lung cancer patients (Part 1)
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
El‐Wakeel et al. Efficacy and tolerability of sildenafil/l‐arginine combination relative to sildenafil alone in patients with organic erectile dysfunction
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
Hasselgren et al. Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole
KR100567717B1 (ko) 알파-글루코시다제 및 알파-아밀라제 억제제를 함유하는영양 보충제
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
DE60232244D1 (de) Nachweis und behandlung von prostatakrebs
Harris et al. Treating Helicobacter pylori--the best is yet to come?
Nemec et al. Systemic use of selective iNOS inhibitor 1400W or non-selective NOS inhibitor l-NAME differently affects systemic nitric oxide formation after oral Porphyromonas gingivalis inoculation in mice
US5904926A (en) Weight loss compound and method of using
Loft et al. Inhibition of antipyrine elimination by disulfiram and cimetidine: the effect of concomitant administration.
Metin et al. Does lidocaine ointment addition increase fluoxetine efficacy in the same group of patients with premature ejaculation?
EP1258248A3 (en) Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application